Reserpine enhances dendritic cell cross-presentation and strengthens CD8+ T cell-mediated antitumor immunity
International Immunopharmacology · 2026-12 · 190 · 117485
DOI: 10.1016/j.intimp.2026.117485 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Yuling Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical College of Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, …. Hauptthemen laut MEDLINE: Dendritic Cells, CD8-Positive T-Lymphocytes, Reserpine, Melanoma, Experimental. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangzhou Municipal Science and Technology Project, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Dendritic cell (DC) cross-presentation is essential for priming tumor-reactive CD8+ T cells, but small-molecule approaches to enhance this process remain limited. A flow-cytometry-based natural-product screen identified reserpine (Res) as a candidate enhancer of antigen cross-presentation. Res increased surface H-2Kb-SIINFEKL presentation in MutuDC cells and Flt3L-derived bone marrow DCs, and Res-conditioned DCs promoted OT-I CD8+ T-cell IFN-γ production and antigen-specific B16-OVA tumor cell killing. In vivo, Res reduced B16 melanoma and MC38 colon tumor growth and improved anti-PD-1 responses in the B16 model. Anti-CD8 and anti-CD11c treatment attenuated Res-associated tumor control, consistent with contributions from CD8+ T cells and CD11c+ cells. Mechanistically, the effect persisted when Res was added after OVA pulsing and washing, and Res did not significantly alter direct peptide loading, fluorescent OVA uptake, or DQ-OVA-reported uptake-associated proteolysis under the tested conditions. Res increased 20S proteasome activity, and MG132, epoxomicin and bortezomib reduced Res-enhanced cross-presentation, supporting the involvement of a proteasome-dependent antigen-processing step. These findings identify Res as an immunopharmacological modulator of DC cross-presentation with potential relevance to antitumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical College of Guangzhou University of Chinese Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Research Center of Integrative Medicine, Scho…
- Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Department of Pathology and Pathophysiology, Guangzhou University of Chinese…
- Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong 999077, China.
- Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
- Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Department of Biochemistry, Guangzhou University of Chinese Medicine, Guangzh…
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006, China; Guangzhou Key Laboratory of Acupuncture and Medicine Research, Guan…
Förderung
- Guangzhou Municipal Science and Technology Project
- China Postdoctoral Science Foundation
Zitieren
APA
Li, Y., Wang, D., Zeng, S., Jiang, Y., Liao, Y., Deng, Y., Ren, Z., Du, Q. S., Ying, Z., Cai, Q., Yi, H., Guan, J., Zhao, T., Jin, H., Zhang, H., & He, L. (2026). Reserpine enhances dendritic cell cross-presentation and strengthens CD8+ T cell-mediated antitumor immunity. International Immunopharmacology, 190, 117485. https://doi.org/10.1016/j.intimp.2026.117485
Vancouver
Li Y, Wang D, Zeng S, Jiang Y, Liao Y, Deng Y, et al. Reserpine enhances dendritic cell cross-presentation and strengthens CD8+ T cell-mediated antitumor immunity. International Immunopharmacology. 2026;190:117485. doi:10.1016/j.intimp.2026.117485
BibTeX
@article{Li2026,
author = {Li, Yuling and Wang, Dingye and Zeng, Shiji and Jiang, Yanjun and Liao, Yuhan and Deng, Yuehua and Ren, Zhenyang and Du, Qing-Song and Ying, Zheng and Cai, Qianwei and Yi, Hua and Guan, Jieying and Zhao, Tingxiu and Jin, He and Zhang, Haibo and He, Lina},
title = {Reserpine enhances dendritic cell cross-presentation and strengthens CD8+ T cell-mediated antitumor immunity},
journal = {International Immunopharmacology},
year = {2026},
volume = {190},
pages = {117485},
doi = {10.1016/j.intimp.2026.117485}
}
EUVIMED